{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:29:15Z","timestamp":1794266955873,"version":"4.9.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"GlaxoSmithKline Investigator-Initiated Study Program","award":["63007497"],"award-info":[{"award-number":["63007497"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19 AI090023"],"award-info":[{"award-number":["U19 AI090023"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1U01AI141919-01"],"award-info":[{"award-number":["1U01AI141919-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We compared glycoprotein E (gE)- and varicella zoster virus (VZV)-specific Th1 immunity in 160 adults, aged 50\u201385 years, randomized to receive live or recombinant zoster vaccine (RZV). gE-specific responses measured by interferon-\u03b3 (IFN-\u03b3) and interleukin 2 (IL-2) dual-color Fluorospot were significantly higher at all time points postimmunization in RZV recipients. VZV-specific IL-2+ memory, but not IFN-\u03b3+ or IFN-\u03b3+IL-2+ effector responses, were higher in RZV recipients at \u22653 months postimmunization. Only RZV recipients maintained higher postvaccination gE-specific IL-2+ and IFN-\u03b3+ and VZV-specific IL-2+ responses for 5 years. The 5-year persistence of VZV-specific memory and gE-specific Th1 immunity may underlie superior RZV efficacy.<\/jats:p>\n               <jats:p>Clinical Trials Registration NCT02114333.<\/jats:p>","DOI":"10.1093\/infdis\/jiab580","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T20:14:15Z","timestamp":1637871255000},"page":"1477-1481","source":"Crossref","is-referenced-by-count":24,"title":["Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence"],"prefix":"10.1093","volume":"225","author":[{"given":"Michael J","family":"Johnson","sequence":"first","affiliation":[{"name":"University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuining","family":"Liu","sequence":"additional","affiliation":[{"name":"Colorado School of Public Health, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashis","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Colorado School of Public Health, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Lang","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron J","family":"Levin","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Weinberg","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"key":"2022041907553550200_CIT0001","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older.","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"2022041907553550200_CIT0002","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2022041907553550200_CIT0003","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"2022041907553550200_CIT0004","article-title":"The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase III clinical trials (ZOE-50 and ZOE-70)","author":"Boutry","journal-title":"Clin Infect Dis"},{"key":"2022041907553550200_CIT0005","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy.","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2022041907553550200_CIT0006","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1172\/JCI109739","article-title":"Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma.","volume":"65","author":"Arvin","year":"1980","journal-title":"J Clin Invest"},{"key":"2022041907553550200_CIT0007","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","article-title":"VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: the SHEZ study.","volume":"37","author":"Asada","year":"2019","journal-title":"Vaccine"},{"key":"2022041907553550200_CIT0008","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1172\/JCI121484","article-title":"Th1 memory differentiates recombinant from live herpes zoster vaccines.","volume":"128","author":"Levin","year":"2018","journal-title":"J Clin Invest"},{"key":"2022041907553550200_CIT0009","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older.","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"2022041907553550200_CIT0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/infdis\/165.1.119","article-title":"Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation.","volume":"165","author":"Wilson","year":"1992","journal-title":"J Infect Dis"},{"key":"2022041907553550200_CIT0011","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/jmv.21173","article-title":"Asymptomatic reactivation and shed of infectious varicella zoster virus in astronauts.","volume":"80","author":"Cohrs","year":"2008","journal-title":"J Med Virol"},{"key":"2022041907553550200_CIT0012","article-title":"Immunogenicity of the adjuvanted recombinant zoster vaccine: persistence and anamnestic response to additional doses administered 10 years after primary vaccination","author":"Hastie","journal-title":"J Infect Dis"},{"key":"2022041907553550200_CIT0013","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fimmu.2015.00553","article-title":"Effector and central memory poly-functional CD4+ and CD8+ T cells are boosted upon ZOSTAVAX(\u00ae) vaccination.","volume":"6","author":"Sei","year":"2015","journal-title":"Front Immunol"},{"key":"2022041907553550200_CIT0014","doi-asserted-by":"crossref","first-page":"e00305-19","DOI":"10.1128\/JVI.00305-19","article-title":"The effect of age on the immunogenicity of the live attenuated zoster vaccine is predicted by baseline regulatory T cells and varicella-zoster virus-specific T cell immunity.","volume":"93","author":"Weinberg","year":"2019","journal-title":"J Virol"},{"key":"2022041907553550200_CIT0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clim.2016.05.007","article-title":"Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial.","volume":"169","author":"Leroux-Roels","year":"2016","journal-title":"Clin Immunol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab580\/41881613\/jiab580.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/8\/1477\/43386960\/jiab580.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/8\/1477\/43386960\/jiab580.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T08:10:04Z","timestamp":1650355804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/8\/1477\/6444689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,27]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,11,27]]},"published-print":{"date-parts":[[2022,4,19]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab580","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,15]]},"published":{"date-parts":[[2021,11,27]]}}}